Brokerages Set Sutro Biopharma, Inc. (NASDAQ:STRO) Target Price at $33.60

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have earned an average rating of “Hold” from the eight analysts that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $33.60.

Several equities research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Sutro Biopharma in a research report on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Sutro Biopharma in a research report on Monday, December 22nd. Wall Street Zen lowered Sutro Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. HC Wainwright boosted their target price on Sutro Biopharma to $10.00 and gave the company a “neutral” rating in a research report on Monday, December 22nd. Finally, Wedbush reissued a “neutral” rating and issued a $100.00 price objective (up previously from $20.00) on shares of Sutro Biopharma in a research note on Tuesday, December 2nd.

Insider Activity

In other Sutro Biopharma news, Director Connie Matsui acquired 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 15th. The stock was bought at an average price of $8.00 per share, for a total transaction of $40,000.00. Following the acquisition, the director directly owned 5,000 shares in the company, valued at $40,000. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders purchased 11,175 shares of company stock worth $89,598. 5.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Catalyst Funds Management Pty Ltd bought a new stake in Sutro Biopharma during the 2nd quarter valued at about $27,000. Bridgeway Capital Management LLC raised its stake in shares of Sutro Biopharma by 232.6% during the third quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock valued at $37,000 after acquiring an additional 30,000 shares in the last quarter. Savant Capital LLC purchased a new stake in shares of Sutro Biopharma in the second quarter valued at approximately $37,000. CWM LLC boosted its holdings in shares of Sutro Biopharma by 73.2% in the second quarter. CWM LLC now owns 56,657 shares of the company’s stock valued at $40,000 after purchasing an additional 23,941 shares during the period. Finally, Vanguard Personalized Indexing Management LLC raised its position in Sutro Biopharma by 174.8% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 60,617 shares of the company’s stock valued at $43,000 after purchasing an additional 38,561 shares in the last quarter. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Stock Performance

STRO opened at $11.52 on Friday. The company has a fifty day moving average of $9.61 and a 200 day moving average of $9.01. Sutro Biopharma has a fifty-two week low of $5.23 and a fifty-two week high of $21.50. The stock has a market capitalization of $98.04 million, a price-to-earnings ratio of -0.44 and a beta of 1.52.

Sutro Biopharma (NASDAQ:STRO) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.25). The firm had revenue of $9.69 million for the quarter, compared to analysts’ expectations of $10.14 million. Sutro Biopharma had a negative net margin of 206.77% and a negative return on equity of 852.70%. On average, equities research analysts forecast that Sutro Biopharma will post -2.92 earnings per share for the current year.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.